Molbio Diagnostics Limited (MOLBIO)
₹1,394.10 +5.73% இன்றைய முடிவு விலை
சுருக்கம்
Molbio Diagnostics Limited closed at ₹1,394.10 on 12 Nov 2026, with an RSI(14) of 55.5. On the daily chart it is in an uptrend, with a technical score of 47/100 (neutral). Data as of 12 Nov 2026.
விலை
- விலை
- ₹1,394.10
- நாள் மாற்றம்
- +5.73%
- சந்தை மதிப்பு
- ₹16,066 கோடி
- 52-வார வரம்பு
- ₹926.35 – ₹1,686.80
- 52-வார உச்சத்திலிருந்து
- -17.35%
- 52-வார தாழ்விலிருந்து
- +50.49%
பங்குச் சந்தை செயல்பாடு12 நவ. 2026
- டெலிவரி
- 11.22% எதிர் சராசரி 20.75%
- வால்யூம் அதன் சராசரியுடன் ஒப்பீடு
- 1.9×
பங்கு உரிமைசெப். 2026
- புரமோட்டர்கள்
- 41.29%
- FII-கள்
- 1.59%
- DIIs
- 19.08%
செப்டம்பர் 2026 உடன் முடிவடைந்த காலாண்டுக்கான பங்குதாரர் விவரம்; சதவீதப் புள்ளிகளில் மாற்றங்கள்.
நிகழ்வுகள்
- சமீபத்திய முடிவுகள்
- Q2 FY27, தாக்கல் செய்யப்பட்டது 6 நவ. 2026
- இயக்குநர் குழுக் கூட்ட அறிவிப்பு
- 5 நவ. 2026
டெக்னிக்கல்ஸ்12 நவ. 2026
- போக்கு
- ஏற்றப் போக்கு
- தொழில்நுட்ப மதிப்பெண்
- 47/100 · நடுநிலை
- MACD
- ஏற்றத்துக்கு சாதகமான (bullish)
- RSI (14)
- 55.51
- ADX (14)
- 19.99
- SuperTrend
- ஏற்றத்துக்கு சாதகமான (bullish)
- 20-நாள் SMA-உடன் ஒப்பீடு
- +3.31%
- 50-நாள் SMA-உடன் ஒப்பீடு
- +5.29%
- அருகிலுள்ள சப்போர்ட்
- ₹1,246.55
- அருகிலுள்ள ரெசிஸ்டன்ஸ்
- ₹1,398.00
பங்குச் சந்தைத் தரவு. ஒவ்வொரு எண்ணும் அதன் சொந்தப் பக்கம் காட்டும் வடிவத்திலேயே; தேதிகள் தரவின் தேதிகள். தகவலுக்கு மட்டுமே, முதலீட்டு ஆலோசனை அல்ல.
📈 பங்கு விலை & நிகழ்வுகள்
Q2 FY27 முடிவுகள்
Molbio Diagnostics Limited reported Q2 FY27 results on 6 Nov 2026: revenue ₹259 Cr, and net profit ₹7.7 Cr; the operating margin was 17.0%.
| Q2 FY27 (₹ கோடி) | மதிப்பு | YoY | QoQ |
|---|---|---|---|
| வருவாய் | ₹259 | — | -35.1% |
| செயல்பாட்டு லாபம் | ₹43.9 | — | -52.0% |
| நிகர லாபம் | ₹7.7 | — | -86.4% |
| EPS (₹) | 1.33 | — | -73.5% |
| செயல்பாட்டு லாப வரம்பு | 17.0% | — | — |
- வரிக்கு முந்தைய லாபத்தில் 33% மற்ற வருமானம் மற்றும் ஒருமுறை கிடைத்த வருமானங்களிலிருந்து வந்தது.
- Behind management's FY27 EBITDA margin guidance of 24–25% (H1 FY27 20.6%)
லாபத்தின் தரம்: வரிக்கு முந்தைய ₹17.5 கோடி லாபத்தில், ₹11.7 கோடி (67%) முக்கிய வணிகத்திலிருந்து வந்தது; மீதம் பிற வருமானம் மற்றும் ஒருமுறை வரவுகளிலிருந்து வந்தது.
நிர்வாகத்தின் முன்னறிவிப்புக்கு எதிராக: FY27 EBITDA லாப வரம்பு ஆக 24–25% என முன்னறிவிக்கப்பட்டிருந்தது (11 நவ. 2026 கான்கால்); H1 FY27 20.6% ஆக பதிவானது, behind it.
முடிவுகள் வெளியானதிலிருந்து பங்கு விலை: -0.7% (அறிவிப்புக்கு முந்தைய முடிவு விலை முதல் சமீபத்திய முடிவு விலை வரை).
MOLBIO டெலிவரி சதவீதம்
க்கான NSE EOD தரவு
On Thu, 12 Nov 2026, 11.22% of the MOLBIO shares traded on NSE were taken to delivery, against the stock's own 20-session average of 20.75%. The price rose 5.73% on unusually low delivery, so more of the move than usual was intraday trading.
கடந்த 5 அமர்வுகளில் டெலிவரி: 24.3% · 21.8% · 21.5% · 45.6% · 11.2%
பங்குச் சந்தை வெளியிட்டவற்றின் விளக்கம், பரிந்துரை அல்ல. "accumulation" அல்லது "லாங் பில்டப்" போன்ற பெயர்கள் எண்களில் உள்ள ஒரு வடிவத்தை குறிக்கின்றன. டெலிவரி எவ்வாறு பகுப்பாய்வு செய்யப்படுகிறது
📢 சமீபத்திய கார்ப்பரேட் அறிவிப்புகள்
Molbio Diagnostics filed the transcript of its Q2 & H1 FY27 earnings call held on November 05, 2026. Consolidated revenue from operations stood at ₹667 crore for H1 FY27 versus ₹680 crore in H1 FY26, impacted by a one-month delay in government rate contract negotiations. H1 EBITDA stood at ₹153 crore (23% margin), including a ₹15 crore EBITDA loss from subsidiary OptraSCAN, while PAT came in at ₹60 crore. Management reaffirmed its full-year guidance of 25% top-line growth and 24-25% EBITDA margins, citing strong expected second-half seasonality (typically 60% of annual revenue) and an export pickup.
- H1 FY27 consolidated revenue stood at ₹667 crore vs ₹680 crore in H1 FY26, with export revenue at ₹120 crore
- Consolidated H1 EBITDA was ₹153 crore (23% margin), burdened by a ₹15 crore EBITDA loss from OptraSCAN
- H1 PAT came in at ₹60 crore, affected by higher interest and amortization from the OptraSCAN acquisition
- Volumes for H1 included 559 devices and 94.7 lakh kits sold
- Management reiterated FY27 guidance of 25% top-line growth and 24% to 25% EBITDA margins
Molbio Diagnostics released its Q2 FY27 investor presentation, reporting a 54% YoY drop in total income to ₹264.8 crore and a sharp 93% YoY drop in PAT to ₹7.7 crore. Management attributed the weakness to rate-contract negotiations taking 1-1.5 months, meaning Q2 did not reflect a full three months of sales. For H1 FY27, total income stood at ₹676.3 crore compared to ₹681.8 crore in H1 FY26, with PAT falling 27% to ₹60.4 crore. Despite the soft quarter, management maintained its guidance of 25% topline growth for full-year FY27, noting that H1 historically represents only 35-45% of annual revenue.
- Q2 FY27 total income fell 54.5% YoY to ₹264.8 crore from ₹581.4 crore in Q2 FY26
- Q2 FY27 PAT declined 92.8% YoY to ₹7.7 crore with net margin shrinking to 2.9% from 18.4%
- H1 FY27 total income stood flat at ₹676.3 crore vs ₹681.8 crore in H1 FY26
- Operating cash flow turned positive to ₹167.1 crore in H1 FY27 vs an outflow of ₹239.3 crore in H1 FY26
- Management reaffirmed full-year FY27 topline growth guidance of 25% over FY26
Molbio Diagnostics announced the outcome of its Board meeting held on November 05, 2026, approving un-audited standalone and consolidated financial results for the quarter and half-year ended September 30, 2026. The Board also reviewed the IPO proceeds Monitoring Agency Report for Q2 FY27. Additionally, the company noted the resignation of Senior Management Personnel Dr. Kuldeep Singh Sachdeva, President and Chief Medical Officer (Partnerships and Advocacy), effective January 21, 2027. Furthermore, M/s Rakesh Hulihalli & Associates was appointed as Secretarial Auditor for a five-year term from FY27 to FY31, subject to shareholder approval.
- Approved un-audited standalone and consolidated financial results for the quarter and half-year ended September 30, 2026, with an unmodified review opinion.
- Noted resignation of Dr. Kuldeep Singh Sachdeva, President & Chief Medical Officer, effective January 21, 2027.
- Approved IPO proceeds utilization Monitoring Agency Report for the quarter ended September 30, 2026.
- Appointed M/s Rakesh Hulihalli & Associates as Secretarial Auditor for five years (FY 2026-27 to FY 2030-31).
Molbio Diagnostics Limited has announced the closure of its trading window starting October 01, 2026, pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015. The restriction applies to all designated persons, insiders, and their immediate relatives ahead of the declaration of unaudited financial results for the quarter ended September 30, 2026. The window will reopen 48 hours after the declaration of the financial results. The specific date for the Board Meeting to consider the results will be communicated separately.
- Trading window closes on October 01, 2026
- Window remains closed until 48 hours after the declaration of Q2 results
- Pertains to financial results for the quarter ended September 30, 2026
Molbio Diagnostics Limited has informed the exchanges that company officials will participate in a virtual group meeting with investors and analysts. The interaction is scheduled for Tuesday, September 22, 2026, starting at 11:00 AM IST. Management stated that discussions will focus on general business outlook and publicly available information, with no unpublished price sensitive information (UPSI) being shared.
- Virtual group meeting scheduled for September 22, 2026
- Meeting start time fixed at 11:00 AM IST onwards
- Discussion restricted to publicly available information with no UPSI to be shared
- Filing made under Regulation 30 of SEBI LODR Regulations, 2015
Molbio Diagnostics released the transcript of its maiden earnings call for Q1 FY27 post-IPO. The company reported a footprint of over 12,500 Truenat machines installed across 90+ countries and cumulative testing surpassing 40 million tests. Management confirmed a recently signed 2-year TB rate contract with the Government of India. In Q1 FY27, Molbio posted a revenue of ₹399.38 crore with a net profit of ₹56.63 crore.
- Installed base reached over 12,500 Truenat machines deployed across 90-plus countries
- Over 40 million tests conducted using the Truenat platform to date across 43 assays covering 30 diseases
- R&D investments expanded to more than ₹2.16 billion over the last 3 years, with 207 registered patents
- Secured a fresh 2-year rate contract for TB testing with the Government of India finalized in August 2026
Molbio Diagnostics Limited has announced a change in its Corporate Identification Number (CIN) from U33125GA2000PLC002909 to L33125GA2000PLC002909, following its equity share listing on NSE and BSE on August 17, 2026. Consequently, its status on the Ministry of Corporate Affairs (MCA) portal has been updated from 'Unlisted' to 'Listed'. The master data shows an authorized capital of Rs 20,00,00,000 and a paid-up capital of Rs 11,52,39,996. This is a purely administrative filing to formalize listed company status with the Registrar of Companies, Goa.
- Equity shares listed on NSE and BSE on August 17, 2026
- CIN changed to L33125GA2000PLC002909 from U33125GA2000PLC002909
- Company status on MCA portal updated from 'Unlisted' to 'Listed'
- Authorised capital stands at Rs 20,00,00,000 and paid-up capital at Rs 11,52,39,996
Molbio Diagnostics Limited has uploaded the audio recording of its earnings call held on September 08, 2026. The call pertained to the company's standalone and consolidated financial results for the quarter ended June 30, 2026. In Q1 FY27, Molbio reported revenue of Rs 399.38 cr and a net profit of Rs 56.63 cr. The audio recording is accessible via the company's website.
- Earnings conference call conducted on September 08, 2026
- Audio recording covers financial results for the quarter ended June 30, 2026
- Recording made accessible to the public on www.molbiodiagnostics.com pursuant to SEBI regulations
Molbio Diagnostics released its Q1 FY27 investor presentation following its recent listing on August 17, 2026. Total income surged to ₹411.5 crore compared to ₹100.5 crore in Q1 FY26, driven by higher Truenat test-kit volumes (6.2 million units vs 0.8 million units). EBITDA turned positive to ₹103.7 crore (25.2% margin) against an EBITDA loss of ₹14.5 crore in Q1 FY26, while PAT stood at ₹52.7 crore compared to a net loss of ₹23.9 crore. Performance also benefited from ₹57 crore of deferred export orders from Q4 FY26 recognized this quarter.
- Q1 FY27 Total Income grew to ₹411.5 Cr vs ₹100.5 Cr in Q1 FY26
- EBITDA swung to ₹103.7 Cr (25.2% margin) from a loss of ₹14.5 Cr in Q1 FY26
- PAT turned positive at ₹52.7 Cr against a net loss of ₹23.9 Cr in Q1 FY26
- Truenat test-kit volumes surged to 6.2 Mn units in Q1 FY27 from 0.8 Mn units in Q1 FY26
- Results included ~₹57 Cr of deferred Q4 FY26 export orders recognized in Q1 FY27
Molbio Diagnostics announced its Q1 FY27 results (its first after listing on August 17, 2026), posting Total Income of ₹411.48 Cr compared to ₹100.47 Cr in Q1 FY26. The company turned profitable with an EBITDA of ₹103.68 Cr (25.20% margin) vs an EBITDA loss of ₹14.50 Cr in Q1 FY26, and a PAT of ₹52.74 Cr vs a net loss of ₹23.94 Cr in Q1 FY26. Performance was driven by Truenat test-kit volume expansion to 6.24 Mn units (up from 0.79 Mn in Q1 FY26), alongside the recognition of ₹57 Cr in deferred export orders from Q4 FY26.
- Total Income surged to ₹411.48 Cr in Q1 FY27 vs ₹100.47 Cr in Q1 FY26
- EBITDA turned positive to ₹103.68 Cr (25.20% margin) vs an EBITDA loss of ₹14.50 Cr in Q1 FY26
- PAT stood at ₹52.74 Cr compared to a net loss of ₹23.94 Cr in Q1 FY26
- Truenat test-kit sales reached 6.24 Mn units vs 0.79 Mn units in Q1 FY26
- Deferred export orders of ~₹57 Cr from Q4 FY26 were recognized in Q1 FY27
Molbio Diagnostics Limited announced the outcome of its Board of Directors meeting held on September 5, 2026. The Board approved the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, subject to limited review by statutory auditors. Additionally, the Board authorized key managerial personnel, including the CEO, CTO, CFO, and Company Secretary, to determine the materiality of events and disclosures under Regulation 30(5) of SEBI LODR Regulations.
- Board approved unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026
- Meeting commenced at 11:47 AM and concluded at 04:00 PM on September 5, 2026
- Four Key Managerial Personnel authorized under Regulation 30(5) for determining disclosure materiality
Molbio Diagnostics Limited has scheduled an earnings conference call for Tuesday, September 8, 2026, at 04:00 PM IST. The management team will discuss the financial performance for the first quarter ended June 30, 2026 (Q1 FY27). Key senior executives, including the CEO, CTO, and CFO, will participate in the call.
- Earnings conference call scheduled for September 8, 2026, at 04:00 PM IST
- Meeting intended to discuss financial results for the quarter ended June 30, 2026 (Q1 FY27)
- Senior management including CEO Sriram Natarajan and CFO Manan Bimal Khokhani to participate
Molbio Diagnostics Limited reported the outcome of its Board of Directors meeting held on August 27, 2026. The Board designated Mr. Darshan Raghunath Karekar as the Compliance Officer under SEBI (Prohibition of Insider Trading) Regulations, 2015. Mr. Karekar is already the existing Compliance Officer under Regulation 6 of SEBI LODR Regulations. The brief meeting commenced at 04:56 PM and concluded at 05:08 PM.
- Board meeting conducted on August 27, 2026, lasting 12 minutes (04:56 PM to 05:08 PM)
- Mr. Darshan Raghunath Karekar designated as Compliance Officer under SEBI (PIT) Regulations, 2015
- Existing role as Compliance Officer under Regulation 6 of SEBI LODR continues unchanged
Molbio Diagnostics Limited has announced the closure of its trading window for insiders and designated persons starting August 21, 2026. The closure is in compliance with SEBI Insider Trading regulations ahead of the declaration of financial results for the quarter ended June 30, 2026. The window will reopen 48 hours after the declaration of the unaudited financial results. The specific date for the board meeting to approve the results will be announced separately.
- Trading window closes effective August 21, 2026
- Applies to all insiders, designated persons, and their immediate relatives
- Trading window reopens 48 hours after Q1 financial results declaration
- Results pertain to the quarter ended June 30, 2026
நிறுவனச் சுயவிவரம்
நிதிச் செயல்திறன்
இந்த நிறுவனத்துக்கான நிதிப் பகுப்பாய்வுத் தரவு இன்னும் கிடைக்கவில்லை.
செயல்பாட்டு உந்துசக்திகள்
இந்த நிறுவனத்திற்கான செயல்பாட்டுப் பகுப்பாய்வுத் தரவு இன்னும் கிடைக்கவில்லை.
வியூக வளர்ச்சி
இந்த நிறுவனத்துக்கான வியூக வளர்ச்சிப் பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
வெளிப்புறக் காரணிகள்
இந்த நிறுவனத்துக்கு வெளிப்புறக் காரணிகளின் பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
ஒழுங்குமுறை & நிர்வாகம்
இந்த நிறுவனத்திற்கான ஒழுங்குமுறைப் பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
அபாயப் பகுப்பாய்வு
இந்நிறுவனத்துக்கான அபாய பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
